Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vbi Vaccines Inc CS (VBIV)

Vbi Vaccines Inc CS (VBIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B PR Newswire - Wed Sep 6, 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.0653 (-50.87%)
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure PR Newswire - Wed Jul 5, 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.0653 (-50.87%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates PR Newswire - Wed Jul 5, 2023

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
ANTX : 1.2300 (-5.38%)
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASLâ„¢ Congress 2023 PR Newswire - Sun Jun 25, 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
VBI Vaccines Appoints Vaughn Himes to Board of Directors Business Wire - Tue Apr 25, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief...

VBIV : 0.0653 (-50.87%)
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split Business Wire - Tue Apr 4, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the Company’s efforts...

VBIV : 0.0653 (-50.87%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results PR Newswire - Fri Mar 24, 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
ANTX : 1.2300 (-5.38%)
VBI Vaccines Reports Full Year 2022 Financial Results Business Wire - Mon Mar 13, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial...

VBIV : 0.0653 (-50.87%)
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat Business Wire - Thu Feb 23, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President...

VBIV : 0.0653 (-50.87%)
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B Business Wire - Wed Feb 15, 2023

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 2 study...

VBIV : 0.0653 (-50.87%)

Barchart Exclusives

S&P Futures Tick Lower Ahead of U.S. PMI Data Barchart - 1 hour ago
December S&P 500 E-Mini futures (ESZ24) are trending down -0.24% this morning as weak Eurozone PMI data cast doubt on the health of the global economy, while investors braced for U.S. business activity data. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot